DI
DEXCOM, INC.
StreetZero Signal 55
About DEXCOM, INC.
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. Its products include Dexcom G7, G6, ONE+, and Stelo. The company is headquartered in San Diego and went public via IPO in 2005.
LATEST FUNDINGRule 144
$142K
Announced 2026-11-16
IN THE NEWS
EMPLOYEES11000
FOUNDED1999
HQSan Diego, CA, United States
Industry
Public Equity (NASDAQ)
Tags
HealthcareMedical DevicesCGMNASDAQ
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- DexCom designs and sells CGM systems including G7 and G6 for diabetes management.
- Completed 2005 IPO raising $56.4 million gross proceeds after inception in 1999.
- Publicly traded on NASDAQ as DXCM with market capitalization of $30.26 billion.
- Headquartered in San Diego with approximately 11,000 employees.
Ask StreetZero about DEXCOM, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account